

Press release July 7, 2022, 08.30 CET.

## **Invitation to presentation of Sedana Medical's interim report for the second quarter 2022**

**Sedana Medical AB (publ) plans to present its interim report for the second quarter 2022 in an audiocast on July 21 at 13.30 CET.**

According to the financial calendar, Sedana Medical plans to publish the report for the second quarter 2022 on Thursday July 21 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Johan Spetz, CFO, and Peter Sackey, CMO, as well as answer questions.

Date: Thursday July 21 2022

Time (CET): 13.30

Link to audiocast: <https://financialhearings.com/event/43301>

Welcome!

**For additional information, please contact:**

Johannes Doll, CEO, +46 (0)76 303 66 66

Johan Spetz, CFO, +46 (0)730 36 37 89

ir@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.

The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

### **About Sedana Medical**

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.